Abstract
Purpose:
To evaluate the effect of pre-surgical intravitreal bevacizumab (IVB) on vitrectomy for proliferative diabetic retinopathy (PDR).
Methods:
IVB was done for PDR eyes (12 consecutive eyes, IVB group) within one week prior to vitrectomy. Those received vitrectomy for PDR without IVB were used as a control (15 eyes, control group). Baseline characteristics of two groups, visual outcome, post-operative hemorrhage were investigated.
Results:
There were no significant difference in the rate of increase of intraocular pressure (IVB group vs control group: 5 eyes VS 6 eyes, P=0.93), macular edema (IVB group vs control group: 11 eyes VS 13 eyes, P=0.69) and visual outcome (pre-operative logMAR: 1.46 VS 1.13 P=0.18, post-operative logMAR: 0.44 VS 0.52 P=0.62) between groups. Frequency of post-operative hemorrhage after 1 months were 4 times/15eyes, in IVB group and 0 times/12eyes in control group (P=0.057). No adverse events related to IVB such as stroke, hypertension, or unknown visual loss were observed during the observation.
Conclusions:
Although the statistics did not reach significance, there was a tendency that pre-surgical IVB would decrease the incidence of hemorrhage after vitrectomy for PDR.
Keywords: 499 diabetic retinopathy •
561 injection •
762 vitreoretinal surgery